Tue, Jul 22, 2014, 8:03 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Coronado Biosciences, Inc. Message Board

  • ding_king2000 ding_king2000 Jul 9, 2013 6:25 PM Flag

    Wow, saw this on motley fool today.

    From another site:
    Whipworm eggs to treat autoimmune disease might sound completely reasonable to some people, but I see it as farfetched to the border of insanity. If you wonder why high level executives and scientists would spend years pursuing a completely irrational scientific endeavor, my answer would be that I don't know but I see it happen all the time. The fact that Coronado management is confident does not make me confident. ... Topline results from the TRUST-1 phase II trial of the magic beans in ulcerative colitis are expected in the second half of 2013, so we don't have too long to wait.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • These negative articles (besides the obvious errors) are usually written by healthy people who haven't a clue. My father had Crohns disease. He was in the emergency room/ hospital almost every year and ended up with several sections of his intestine removed. He was on constant guard against another attack. I'm sure the medicines are better today; but, I can guarantee that he would have had no reservations about taking TVO's if they were available.

    • why is that "Wow"? MF quoting 1 out of tens of thousands of "fools" in an article that could be published in a tweet. LOL. MF published the same non-article twice. Did you notice that the guy quoted doesn't even know the trial is for Crohn's, not ulcerative colitis? That is some DD he must have done. Good luck on your short but you might consider covering it well before October, at which point the PPS of CNDO is going to go berserk.

 
CNDO
1.64-0.06(-3.53%)Jul 22 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.